Barclays: 'We think dropping the question of '441 validity from the case is a major development'.The analyst comments "We think ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'April 28, 2026 2:00 PM Barclays on BridgeBio Pharma (BBIO): 'We see buying opportunity on weakness, reiterate top idea'April 28, 2026 12:14 PM TD Cowen on BridgeBio Pharma (BBIO): 'A key overhang is removed now'April 28, 2026 11:46 AM Mizuho on BridgeBio Pharma (BBIO): 'Not Best Case but Still Good Outcome Relative to Street'April 28, 2026 11:25 AM Mizuho: 'BBIO could potentially trade in the $90-110+ range today / near-term'April 28, 2026 9:48 AM RBC on Pfizer (PFE): 'Litigation overhang cleared'April 28, 2026 9:46 AM